NovaBridge Biosciences
NBP · XNASCIK 1778016fmd_08RS36FGZCZ24J41DBRSTF5HXCManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Dec 31, 2025, 18 periods
Latest annual · FY2023
Millions- Total revenues
- 28
- Gross profit
- (249)
- Net income
- (1,466)
- Free cash flow
- (1,316)
Latest quarter · Q4 FY2019
Millions- Total revenues
- 0
- Net income
- 1,042
- Free cash flow
- 1,013
Daily close · NBPIEX trades only
Dec 18, 2025 to Nov 11, 2026 · 226 sessions0.86 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- -73.8%
- Revenue, 5 yearsFY2018 to FY2023
- -12.5%
- Net income, 5 yearsFY2018 to FY2023
- n/m
NovaBridge Biosciences (NBP) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | CN¥27.6 million | -CN¥221.6 million | 20-F 2024-04-30 · proof | |
| Net income | -CN¥1.5 billion | -CN¥2.5 billion | 20-F 2024-04-30 · proof | |
| Cash from operating activities | -CN¥1.3 billion | -CN¥1.1 billion | 20-F 2024-04-30 · proof | |
| Free cash flow | -CN¥1.3 billion | -CN¥1.1 billion | 20-F 2024-04-30 · proof | |
| Total assets | CN¥2.6 billion | CN¥4.1 billion | -35.9% | 20-F 2024-04-30 · proof |
| Total liabilities | CN¥894.8 million | CN¥1.2 billion | -23.1% | 20-F 2024-04-30 · proof |
| Cash and cash equivalents | CN¥2.1 billion | CN¥3.2 billion | -33.4% | 20-F 2024-04-30 · proof |
- What was NovaBridge Biosciences (NBP)'s revenue in fiscal 2023?
- NovaBridge Biosciences (NBP) reported revenue of CN¥27.6 million for fiscal 2023 (the year ended Dec 31, 2023), against -CN¥221.6 million the year before. Source: the 20-F filed with the SEC on Apr 30, 2024. SEC
- What was NovaBridge Biosciences (NBP)'s net income in fiscal 2023?
- NovaBridge Biosciences (NBP) reported net income of -CN¥1.5 billion for fiscal 2023 (the year ended Dec 31, 2023), against -CN¥2.5 billion the year before. Source: the 20-F filed with the SEC on Apr 30, 2024. SEC
- What was NovaBridge Biosciences (NBP)'s cash from operating activities in fiscal 2023?
- NovaBridge Biosciences (NBP) reported cash from operating activities of -CN¥1.3 billion for fiscal 2023 (the year ended Dec 31, 2023), against -CN¥1.1 billion the year before. Source: the 20-F filed with the SEC on Apr 30, 2024. SEC
- What was NovaBridge Biosciences (NBP)'s free cash flow in fiscal 2023?
- NovaBridge Biosciences (NBP) reported free cash flow of -CN¥1.3 billion for fiscal 2023 (the year ended Dec 31, 2023), against -CN¥1.1 billion the year before. Source: the 20-F filed with the SEC on Apr 30, 2024. SEC
- What are NovaBridge Biosciences (NBP)'s total assets?
- As of Dec 31, 2023, NovaBridge Biosciences (NBP) reported total assets of CN¥2.6 billion, against CN¥4.1 billion a year earlier (-35.9%). Source: the 20-F filed with the SEC on Apr 30, 2024. SEC
- What are NovaBridge Biosciences (NBP)'s total liabilities?
- As of Dec 31, 2023, NovaBridge Biosciences (NBP) reported total liabilities of CN¥894.8 million, against CN¥1.2 billion a year earlier (-23.1%). Source: the 20-F filed with the SEC on Apr 30, 2024. SEC
- What are NovaBridge Biosciences (NBP)'s cash and cash equivalents?
- As of Dec 31, 2023, NovaBridge Biosciences (NBP) reported cash and cash equivalents of CN¥2.1 billion, against CN¥3.2 billion a year earlier (-33.4%). Source: the 20-F filed with the SEC on Apr 30, 2024. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:NBP&period_type=annual&limit=5"Information only, not investment advice.